Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen and Princeton Biomeditech to Develop Heart Failure IVD

NEW YORK, Jan. 19 (GenomeWeb News) - Nanogen has signed a manufacturing and distribution agreement with Princeton Biomeditech to develop a point-of-care in vitro diagnostic assay that detects NT-proBNP, a marker of heart failure, Nanogen said yesterday in documents filed with the US Securities and Exchange Commission.


According to the terms of the agreement, Nanogen will develop reagents that PBM will incorporate into a final product. Nanogen will be responsible for clinical trials necessary for regulatory approval. PBM will develop a reader for the test, half of whose development will be funded by Nanogen, and the company will seek regulatory approval for the device as well.


PBM will have the right to a nonexclusive license or supply aggreement for Nanogen reagents for detecting biomarkers related to congestive heart failure, stroke, or traumatic brain injury. PBM will manufacture the test and its reader, and it gains limited distribution rights.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.